RxDoctor Payments Data

Joseph Badeaux, MD

Otolaryngology · Alexandria, LANPI 1346244852

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,500 of the $3,396 with a category attached, or 73.6%. Spirair, Inc. accounts for 78.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $2,807 and has fallen 92.8% since, to $203 in 2025.

$3,396in general payments, 2019–2025

Across 44 payments — averaging $77.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spirair, Inc.$3K
  • Sanofi$171
  • GSK$129
  • Aerin Medical Inc.$127
  • Acclarent, Inc$61
  • Integra Lifesciences Corporation$60
  • plus $197 from 7 others

What the payments were for

  • Consulting fees$2,50074%
  • Food & beverage$89626%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,396 in reported general payments places this provider in the 75th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$249,999
Medicare patients
844
Services billed
2,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab12$51,723
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth41$4,580
Ipratropium Bromide148$3,801
Azelastine Hcl143$3,095
SynthroidLevothyroxine Sodium47$2,176
Cevimeline Hcl21$2,176
Cefdinir72$1,533
Fluticasone Propionate127$1,437
Tobramycin-DexamethasoneTobramycin/Dexamethasone31$1,264
Levothyroxine Sodium241$1,264
Pilocarpine Hcl17$1,061
Gabapentin65$831
Mupirocin105$799
Ofloxacin40$770
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen58$730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$45$2,17647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 218 otolaryngology providers in Louisiana.

Other otolaryngology in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →